ABBV vs NKE: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and NIKE, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
NIKE, Inc. · Consumer Cyclical
$42.62
+38.4% upside to fair value
Med Conviction
Grade B+
QuantHub Verdict
NKE has more upside to fair value
(+38.4%).
NKE trades at a lower forward P/E
(27.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
NKE |
| Current Price |
$197.69 |
$42.62 |
| Fair Value Estimate |
$210.22 |
$58.98 |
| Upside to Fair Value |
+6.3%
|
+38.4%
|
| Market Cap |
$349.7B |
$63.0B |
| Forward P/E |
83.3x
|
27.9x
|
| EV / EBITDA |
23.4x
|
20.7x
|
| Price / Sales |
5.7x
|
1.4x
|
| Price / FCF |
18.7x
|
19.4x
|
| Revenue Growth YoY |
+10.0%
|
-9.8%
|
| Gross Margin |
70.2%
|
42.7%
|
| Operating Margin |
26.7%
|
8.0%
|
| Return on Equity |
-361.6%
|
24.4%
|
| Dividend Yield |
0% |
3.8% |
| FCF Yield |
5.35%
|
5.2%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Nike is the world's largest athletic footwear and apparel company with $46.3B in FY2025 revenue, operating across 190+ countries with the Nike, Jordan, and Converse brands. The stock trades near its 9-year low at $42.62 after an 11% single-day crash following a Q3 FY2026 earnings report that showed 35% net income decline and weak Q4 guidance calling for a further 2-4% revenue decline. FY2025 reve…
Accumulation Zones
| Metric |
ABBV |
NKE |
| Zone Low |
$157.66 |
$44.23 |
| Zone High |
$178.69 |
$50.13 |
| In Buy Zone? |
No
|
Yes
|